Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer | Zendy

Julien Mazières | Zendy; Dariusz M. Kowalski | Zendy; Alexander Luft | Zendy; David Vicente | Zendy; Ali Tafreshi | Zendy; Mahmut Gümüş | Zendy; К. К. Лактионов | Zendy; Bárbara Hermes | Zendy; İrfan Çiçin | Zendy; Jerónimo Rafael RodríguezCid | Zendy; Jonathan Wilson | Zendy; Terufumi Kato | Zendy; Rodryg Ramlau | Zendy; Silvia Novello | Zendy; Sreekanth Reddy | Zendy; HansGeorg Kopp | Zendy; Bilal Piperdi | Zendy; Xiaodong Li | Zendy; Thomas Burke | Zendy; Luis PazAres | Zendy

Open Access

Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer

Author(s) -

Julien Mazières,

Dariusz M. Kowalski,

Alexander Luft,

David Vicente,

Ali Tafreshi,

Mahmut Gümüş,

К. К. Лактионов,

Bárbara Hermes,

İrfan Çiçin,

Jerónimo Rafael RodríguezCid,

Jonathan Wilson,

Terufumi Kato,

Rodryg Ramlau,

Silvia Novello,

Sreekanth Reddy,

HansGeorg Kopp,

Bilal Piperdi,

Xiaodong Li,

Thomas Burke,

Luis PazAres

Publication year - 2019

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.01348

Subject(s) - medicine , carboplatin , pembrolizumab , lung cancer , paclitaxel , placebo , quality of life (healthcare) , oncology , cancer , chemotherapy , pathology , immunotherapy , cisplatin , nursing , alternative medicine

In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free survival, and objective response rate in patients with previously untreated metastatic squamous non-small-cell lung cancer (NSCLC), with little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research